Cargando…

Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management

An observational study describing the number and type of chronic conditions and medications taken by diabetic patients with NAFLD and identifying characteristics that may impact liver disease severity or clinical management. Adults with type 2 diabetes have a high prevalence of nonalcoholic fatty li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Preya Janubhai, Hayward, Kelly Lee, Rudra, Rathiga, Horsfall, Leigh Ula, Hossain, Fabrina, Williams, Suzanne, Johnson, Tracey, Brown, Nigel Neil, Saad, Nivene, Clouston, Andrew Donald, Stuart, Katherine Anne, Valery, Patricia Casarolli, Irvine, Katharine Margaret, Russell, Anthony William, Powell, Elizabeth Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2017
Materias:	4500
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500016/ https://www.ncbi.nlm.nih.gov/pubmed/28658094 http://dx.doi.org/10.1097/MD.0000000000006761

Ejemplares similares

A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary Care
por: Patel, PreyaJanubhai, et al.
Publicado: (2018)

Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease
por: Patel, Preya J., et al.
Publicado: (2017)

Epidemiology of ascites fluid infections in patients with cirrhosis in Queensland, Australia from 2008 to 2017: A population-based study
por: Ratnasekera, Isanka U., et al.
Publicado: (2022)

CONSORT-Characteristics and metabolic phenotype of gut microbiota in NAFLD patients
por: Ge, Haize, et al.
Publicado: (2022)

Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD
por: Sapmaz, Ferdane, et al.
Publicado: (2016)

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD)
por: Golabi, Pegah, et al.
Publicado: (2018)

Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation
por: Gadd, Victoria L., et al.
Publicado: (2016)

FIB-4 is closer to FibroScan screen results to detecting advanced liver fibrosis and maybe facilitates NAFLD warning
por: Ding, Yuping, et al.
Publicado: (2023)

Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD): A PRISMA-compliant systematic review and network meta-analysis
por: Sawangjit, Ratree, et al.
Publicado: (2016)

Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease
por: Irvine, Katharine M., et al.
Publicado: (2021)

Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence: A protocol for a Bayesian network meta analysis
por: Sun, Yuli, et al.
Publicado: (2021)

Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
por: Romero-Gomez, Manuel, et al.
Publicado: (2020)

Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial
por: Hayward, Kelly L., et al.
Publicado: (2017)

Predicting Liver‐Related Outcomes in People With Nonalcoholic Fatty Liver Disease: The Prognostic Value of Noninvasive Fibrosis Tests
por: Johnson, Amy L., et al.
Publicado: (2021)

Multimorbidity or polypharmacy: two sides of the same coin?
por: Sinnott, Carol, et al.
Publicado: (2015)

Multimorbidity, polypharmacy, and mortality in older patients with pacemakers
por: Goto, Toshihiko, et al.
Publicado: (2021)

Italian guidelines on management of persons with multimorbidity and polypharmacy
por: Onder, Graziano, et al.
Publicado: (2022)

Effectiveness of patient‐oriented education and medication management intervention in people with decompensated cirrhosis
por: Hayward, Kelly L., et al.
Publicado: (2020)

Medication‐Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention
por: Hayward, Kelly L., et al.
Publicado: (2019)

Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety
por: Hayward, Kelly L., et al.
Publicado: (2021)

Multimorbidity and polypharmacy: a risk factor for older patients
por: Cucinotta, Domenico
Publicado: (2022)

Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis
por: Hayward, Kelly L, et al.
Publicado: (2017)

Comment on “Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review”
por: Valery, Patricia Casarolli, et al.
Publicado: (2021)

Polypharmacy in multimorbid older adults: protocol for a systematic review
por: Sirois, Caroline, et al.
Publicado: (2017)

Changes in prescribed medicines in older patients with multimorbidity and polypharmacy in general practice
por: von Buedingen, Fiona, et al.
Publicado: (2018)

Trends in multimorbidity and polypharmacy in the Flemish-Belgian population between 2000 and 2015
por: van den Akker, Marjan, et al.
Publicado: (2019)

Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort
por: McQueenie, Ross, et al.
Publicado: (2020)

Polypharmacy Patterns in Multimorbid Older People with Cardiovascular Disease: Longitudinal Study
por: Villén, Noemí, et al.
Publicado: (2022)

Multimorbidity and polypharmacy in hospitalized older patients: a cross-sectional study
por: Zhao, Yong, et al.
Publicado: (2023)

Prevalence of medication discrepancies in patients with cirrhosis: a pilot study
por: Hayward, Kelly L., et al.
Publicado: (2016)

Polypharmacy and medication deprescribing: A survey among multimorbid older adults in Denmark
por: Schiøtz, Michaela L., et al.
Publicado: (2018)

Longitudinal data of multimorbidity and polypharmacy in older adults in Taiwan from 2000 to 2013
por: Lai, Shih-Wei, et al.
Publicado: (2020)

Impact of Multimorbidity and Polypharmacy on Clinical Outcomes of Elderly Chinese Patients with Atrial Fibrillation
por: Kotalczyk, Agnieszka, et al.
Publicado: (2022)

Correction: Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort
por: McQueenie, Ross, et al.
Publicado: (2021)

Multiplex Serum Protein Analysis Identifies Novel Biomarkers of Advanced Fibrosis in Patients with Chronic Liver Disease with the Potential to Improve Diagnostic Accuracy of Established Biomarkers
por: Irvine, Katharine M., et al.
Publicado: (2016)

Implementing the right care in the right place at the right time for non-alcoholic fatty liver disease (NAFLD-RRR study): a study protocol for a community care pathway for people with type 2 diabetes
por: Gracen, Lucy, et al.
Publicado: (2022)

Obesity and Polypharmacy among African American Older Adults: Gender as the Moderator and Multimorbidity as the Mediator
por: Assari, Shervin, et al.
Publicado: (2019)

Multimorbidity and Polypharmacy in Chinese Emergency Department Patients With Atrial Fibrillation and Impacts on Clinical Outcomes
por: Wang, Juan, et al.
Publicado: (2022)

Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review
por: O’Shea, Joseph, et al.
Publicado: (2022)

The evolution of an evidence based intervention designed to improve prescribing and reduce polypharmacy in older people with multimorbidity and significant polypharmacy in primary care (SPPiRE)
por: McCarthy, Caroline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_30hv4j40g709182keqp80ios1r